Advanced Ovarian Cancer Clinical Trial
Official title:
Multicentric Single Arm Phase II Clinical Trial, to Evaluate Safety and Efficacy of the Combination of Olaparib and PLD for Platinum Resistant Ovarian Primary Peritoneal Carcinoma, and Fallopian Tube Cancer Patients.
Impact of the combination of Olaparib and Pegylated Liposomal Doxorubicin on improvement of progression-free survival at 6 months in patients with platinum resistant advanced ovarian cancer.
The combination of Poly (ADP-ribose) polymerase (PARP) inhibitors with PLD may provide a synergistic effect in patients with advanced ovarian cancer, especially those with Homologous recombination deficiency (HRD), because of the decreased ability to repair chemotherapy-induced DNA damage. Preclinical studies with PARP inhibitors have shown potentiation of the cytotoxic effects of chemotherapeutic agents and a recent phase I study has shown the tolerability of the combination and efficacy in recurrent ovarian cancer. In this study, encouraging efficacy results were seen in ovarian cancer patients and were not limited by Germline BRCA1/2 (gBRCA) Mutations status or sensitivity to platinum therapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03611179 -
Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06055348 -
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT04135521 -
Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer
|
||
| Completed |
NCT01462149 -
Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer
|
Phase 2 | |
| Terminated |
NCT03292172 -
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT05794659 -
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT04360629 -
Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer
|
N/A | |
| Completed |
NCT00516724 -
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
|
Phase 1 | |
| Completed |
NCT03158935 -
The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
|
Phase 1 | |
| Completed |
NCT05775549 -
A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer
|
||
| Active, not recruiting |
NCT03737643 -
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
|
Phase 3 | |
| Completed |
NCT01290471 -
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT04862325 -
SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS
|
N/A | |
| Completed |
NCT01989546 -
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04556539 -
Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04065009 -
The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT01844986 -
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
|
Phase 3 | |
| Not yet recruiting |
NCT05924776 -
Plasmodium Immunotherapy for Advanced Ovarian Cancer
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03878849 -
Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®
|
Phase 2 |